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and Karthik Kasirajan, MD,a Atlanta, Ga
Introduction:Contradictory outcomes exist for different methods of carotid artery revascularization. Here we provide the
comparative rates of adverse events in patients after carotid endarterectomy (CEA), carotid artery stenting (CAS) with a
distal embolic protection device (EPD), and CAS with a proximal flow reversal system (FRS) from a single institution by
various specialists treating carotid artery disease.
Methods: Procedural billing codes and the electronic medical records of patients undergoing revascularization for carotid
artery stenosis from February 2007 through March 2010 were used for data collection. Primary outcome was the
incidence of cerebrovascular accident (CVA), myocardial infarction (MI), or death after CEA and CAS. Each practitioner
determined the choice of therapy, with five of the 14 specialists providing both CAS and CEA. Baseline characteristics
were examined for effect on outcome. Planned comparisons between and within groups were analyzed using 2, t tests,
and analysis of variance, as appropriate.
Results: A total of 495 procedures were documented, comprising 226 CEA, 216 CAS with EPD, and 53 CAS with FRS.
Preoperative comparisons of patient comorbidities were similar among the cohorts. The carotid artery stenosis was symptom-
atic in 42% of these patients. Prior CEA was an indication for CAS rather than another CEA (P < .001). Significantly fewer
patients undergoing CEA were receiving preoperative antiplatelet therapy (P< .001). The groups did not differ significantly
in the overall composite endpoint of death,CVA, andMI (4%, 5.1%, 0%;P .1) or any individualmajor adverse event.Overall,
patients undergoing CAS with EPD had a statistically significant greater incidence of minor CVAs than CEA patients (P 
.031), which was driven by the increased CVA risk for asymptomatic patients. Secondary end points occurred rarely (<2%).
There have been no reoperations or interventions in these patients to date within this institution.
Conclusions:We have established a similar and low incidence ofMI, CVA, and death among patients undergoing CEA and
CAS, of whom approximately 40% were symptomatic. FRS provided superior results in this series; however, its use was
limited to 20% of the CAS procedures. Still, zero adverse events in this cohort make FRS an exciting technology that
warrants a large-scale prospective comparative study. (J Vasc Surg 2011;54:1000-5.)
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eContradictory results and conclusions have recently
been published with respect to carotid artery revascular-
ization as a therapy for carotid artery stenosis. Surgical
management of significant carotid artery disease, as de-
fined historically by the North American Symptomatic
Carotid Endarterectomy Trial (NASCET) and Asymp-
tomatic Carotid Atherosclerosis Study (ACAS), cur-
rently remains the gold standard for reducing the risk of
a subsequent cerebrovascular accident (CVA).1,2 How-
ever, tradeoffs exist when deciding between carotid end-
arterectomy (CEA) or carotid artery stenting (CAS).
Despite several large, multicenter trials that have been
conducted to determine the risks and benefits of each
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1000rocedure, the literature remains unclear about the ab-
olute benefit of one procedure over the other.3-8
Recent data from the Carotid Revascularization End-
rterectomy vs. Stent Trial (CREST) demonstrate an
ncreased risk of CVA among patients undergoing CAS
ompared with CEA (4.1% vs 2.3%) and a decreased risk
f myocardial infarction (MI) in CAS compared with
EA (1.1% vs 2.3%), leading to similar outcomes when
ombining death, MI, and CVA events.3 Further con-
ounding broad consensus is the applicability of these
uperior results to practices outside the trial sites by
hysicians who prefer one mode of therapy rather than
he other.
In addition, the technology used with CAS has ad-
anced tremendously during the past decade, including
ncreased familiarity of practitioners with the technique and
he advent of new stents and distal protection devices
aking randomized controlled trials’ studies of the past,
ather than present. CREST, in particular, used one distal
rotection device that has subsequently been modified.
ospital databases at high-volume institutions may provide
ore rapid dissemination of results as well as aligning
esults with physician behaviors to provide a real-world
xperience to more completely understand competing
herapies.
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Volume 54, Number 4 Brewster et al 1001The aim of this study was to investigate comparative
rates of adverse events in patients after CEA, CAS with a
distal embolic protection device (CAS  EPD), and CAS
with a proximal flow reversal system (CAS  FRS) at a
single institution by various specialists (vascular surgeons,
cardiologists, and neurosurgeons) who treat carotid artery
disease. Given the diversity of specialties represented, the large
number of patients undergoing therapy, and the use of a new
technology (ie, CAS  FRS), this study is unique in the
literature and provides real-world insight into the expected
benefits and limitations of both CEA and CAS (EPD and
FRS), which will be useful to clinicians when they choose the
therapy that is best suited to their patients.
METHODS
Institutional Review Board approval was obtained to
retrospectively review out institution’s collective experi-
ence with CEA, CAS  EPD, and CAS  FRS between
February 2007 and March 2010. Electronic medical re-
cords, procedural billing codes, and clinical visit documen-
tation were analyzed and compiled into an Access database
(Microsoft Corp, Redmond, Wash). Preoperative demo-
graphics collected included age, sex, renal function hyper-
tension, diabetes mellitus, hyperlipidemia, smoking
history, history of MI and CVA, preoperative antiplatelet
regimen, and history of carotid revascularization. Disease-
specific characteristics included presence of symptoms (as
defined by NASCET criteria and physician judgment),
degree of stenosis, methods of imaging, and postoperative
follow-up course. In most patients, the degree of stenosis
was quantified by a procedural arteriogram for CAS and by
duplex ultrasound imaging for CEA. The individual prac-
titioners chose the therapy, with five of the 14 specialists
providing both CAS and CEA.
The primary outcome measure was a combined end
point of CVA, MI, or death 30 days after the interven-
tion. MI was defined as a clinically significant ischemic
cardiac event. Secondary outcomes included length of stay
(LOS), transient neurologic deficits, hyperperfusion syn-
drome, bradycardic/hypotensive sequela, and hematomas.
Patient cohorts were grouped by CAS and CEA. CAS
was further divided into CAS  EPD and CAS  FRS.
Table I. Primary events at 30 days
Eventa
CEA
(n  226)
CAS  EPD
(n  216)
Major adverse event 4.0 (8) 5.1 (9)
Stroke 2.0 (4) 4.0 (7)
Minor stroke 0.5 (1) 3.4 (6)
Major stroke 1.5 (3) 0.6 (1)
Myocardial infarction 0.0 (0) 0.0 (0)
Death (n  425) 1.5 (3) 1.7 (3)
CAS, Carotid artery stenting; CEA, carotid endarterectomy; EPD, embolic
aData are presented as percentage (n).
bCEA/EPD: comparison of CEA vs CAS  EPD; CEA/FRS: comparisonAdmission records were used to identify patients who were aransferred to an intensive care unit (ICU) after the proce-
ure, their hospital LOS, and their likelihood of being
ischarged to home vs to a rehabilitation or subacute
ursing facility.
Planned comparisons were analyzed between CEA and
AS cumulatively, between the two protection cohorts
ithin CAS, and between asymptomatic and symptomatic
atients in each group. Planned comparisons between and
ithin groups were analyzed using Fisher exact, 2, t tests,
nd analysis of variance as appropriate.
ESULTS
During the 3-year study period, 495 procedures were
erformed at one institution by 14 physicians, consisting of
26 CEA and 269 CAS, of which 216 were CAS  EPD
80.1%) and the remaining 53 were CAS  FRS. Moni-
ored anesthesia control was used for 35.8% of the CEAs,
nd 64.2% were completed under general anesthesia. There
as no difference among the groups in the mode average
ercentage stenosis (80% to 99% in all three groups),
he composite primary end points for CEA, CAS  EPD,
nd CAS  FRS (4%, 5.1%, 0%; P  .1), or among groups
ithin any particular primary end point (Table I). No
rimary end point events occurred in the CAS  FRS
ohort. Among practitioners performing both CEA and
AS, combined primary outcomes were also similar (P 
44). In 16 CEA patients and in 10 CAS patients, the
rocedure was done first with a combined cardiac surgical
ntervention.
All CVAs in these patients were ipsilateral and all but
ne occurred on postoperative day 0 or 1, with the excep-
ion being a CAS  EPD patient on postoperative day 3.
our CVAs (three major) occurred in patients after CEA,
nd all performed in symptomatic patients under general
nesthesia. Seven CVAs occurred in the CAS  EPD
roup, four of which occurred in asymptomatic patients (all
inor in prior asymptomatic patients). Of the three symp-
omatic patients who developed CVA after CAS, one CVA
ed to the patient’s death. Overall, the CAS EPD patients
ad a greater incidence of minor CVAs compared with
EA patients, which was statistically significant (P .049).
his significance was more obvious when only asymptom-
CAS  FRS
(n  53)
P b
Overall CEA/EPD CEA/FRS
0.0 (0) .100 .61 .15
0.0 (0) .131 .26 .18
0.0 (0) .070 .031 .50
0.0 (0) .400 .36 .24
0.0 (0) . . . . . . . . .
0.0 (0) .464 .88 .24
tion device; FRS, flow reversal system.
A vs CAS  FRS.protectic patients were compared (P  .032). However, when
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October 20111002 Brewster et alpatients who had FRS protection with EPD were included
in the overall CAS group, this difference was no longer
statistically significant (P  .06).
Three perioperative deaths occurred in each group.
The three deaths in the CEA group occurred after subse-
quent cardiac surgery (two coronary artery bypass graft
procedures, one valvuloplasty). Two of the three CEAs
were completed under local anesthesia and all were done
preemptively for asymptomatic disease; their deaths were
not related directly to the CEA but rather due to compli-
cations after their cardiac operations. Of the three deaths
that occurred after CAS, one was due to a major CVA. One
was related to an aspiration in a patient who required a
groin exploration for retroperitoneal hematoma related to
the CAS, and one was related to readmission 2 weeks after
CAS with respiratory failure, likely due to pneumonia.
Secondary end points occurred rarely (2%) and were
not significantly different between groups (Table II).
Preoperative comparisons of age, sex, preoperative sta-
tin therapy, renal function, hypertension, diabetes mellitus,
history of prior MI, and other comorbidities were similar
among the groups. The carotid artery stenosis was symp-
tomatic in 42% of these patients and was similar among the
groups. History of CVA was more common in the CEA
group than in the CAS EPD cohort (P .03); however,
a prior CVA did not predict postoperative adverse events.
Recurrent carotid artery stenosis after a prior CEA and
contralateral occlusion were predictors for CAS vs CEA
(P  .05). Significantly fewer patients undergoing CEA
were taking preoperative clopidogrel (P  .05); however,
none of the patients identified had an adverse event.
Despite the similar burden of cardiovascular disease and
diabetes, patients undergoing CAS FRS had significantly
less hyperlipidemia (69% vs 82% and 87%; P  .014) and
therapy with acetylsalicylic acid or warfarin on discharge
(P  .05; Table III). There have been no reoperations or
interventions in these patients to date within this institu-
tion.
Significantly more patients in the CEA group required
ICUmonitoring than the CAS group (41.6% vs 27.7%; P
.006). All major complications after CEA occurred in pa-
Table II. Secondary end points at 30 days
End pointa
CEA
(n  226)
CAS  EPD
(n  216)
Transient ischemic attack 1.5 (3) 1.1 (2)
Troponin leak 1.0 (2) 0.6 (1)
Hyperperfusion syndrome 1.0 (2) 0.0 (0)
Bradycardia/hypotension NA 1.1 (2)
Groin complication NA 1.7 (3)
Hematoma 0.5 (1) NA
Cranial nerve palsy 1.0 (2) NA
CAS, Carotid artery stenting; CEA, carotid endarterectomy; EPD, embolic
aData are presented as percentage (n).
bCEA/EPD: comparison of CEA vs CAS  EPD; CEA/FRS: comparisontients in the ICU, with the exception of one minor CVA. tfter CAS, however, only half of the deaths and CVAs had
ccurred when patients were in the ICU.
The CEA group also had a significantly greater LOS
2.9  3.4 vs 1.6  1.9 days; P  .0001), and the mode
verage was 2 days and 1 day, respectively. This was inde-
endent of both MI and CVA as complications of the
rocedures (2.7  3.4 vs 1.5  1.9 days; P  .0001) and
as unrelated to patient age.
Finally, 11 of 223 patients were discharged to rehabil-
tation facilities after CEA vs five of 266 patients after CAS,
hich was significant (P  .05). Discharge to a rehabilita-
ion facility because of CVA/MI occurred in four of 11
atients after CEA and in four of five after CAS. Age was
ot related to these differences (Table IV).
Because this work involves two hospitals, we queried
ractitioners to see if ICU or LOS was related to physician
ractice or not. After CEA, we found ICU stay was signif-
cantly more common at one of our hospitals (31 of 56 vs
3 of 218; P  .001), but LOS was not significantly
ifferent (2.2 days vs 1.6 days; P  .11).
ONCLUSIONS
We have established a similar and low incidence of MI,
VA, and death among patients undergoing CEA and CAS
n 495 patients, of whom 40% were symptomatic. No
eurologic or other primary events occurred in the CAS 
RS group. Four CVAs occurred in symptomatic CEA pa-
ients, with three being major CVAs, whereas one of three
VAs weremajor CVAs in patients undergoing CASEPD.
or asymptomatic patients, no CVAs occurred in patients
ndergoing CEA, and four minor CVAs occurred in pa-
ients undergoing CAS  EPD. The CREST trial demon-
trated that even minor CVAs may have a more clinically
elevant affect on patients’ quality of life than troponin
eaks or non–ST-elevation MI. Thus, we agree with the
REST investigators that CAS  EPD for asymptomatic
isease deserves scrutiny and that this population warrants
urther study. The reason for the increased prevalence of
troke in asymptomatic patients after CAS is not clear, and
his experience was not powered to support this relation-
hip; however, it is tempting to attribute these findings to
CAS  FRS
(n  53)
P b
Overall CEA/EPD CEA/FRS
0.0 (0) .507 .75 .24
0.0 (0) .611 .63 .34
2.0 (1) .173 .11 .59
2.0 (1) .654 . . . . . .
0.0 (0) .219 . . . . . .
NA . . . . . . . . .
NA . . . . . . . . .
tion device; FRS, flow reversal system; NA, not applicable.
A vs CAS  FRS.proteche placement of the distal EPD.
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Volume 54, Number 4 Brewster et al 1003Although the FRS provided perfect results in this series,
its use was limited to 20% of the carotid artery CAS proce-
dures and the prevalence of hyperlipidemia was less. Still,
zero primary events in this cohort compared with the
infrequent but not inconsequential adverse events in the
CEA and CAS groups make this an exciting technology
for the prevention of harm during carotid artery therapy.
Logically, the decreased event rate may be due to not
crossing carotid artery lesions to deploy the EPD. In
support of this finding, the Embolic Protection with
Flow Reversal (EMPIRE) trial did not find evidence of
major ischemic stroke with the use of FRS.9
During a 3-year period, patients undergoing CAS were
significantly less likely to be in the ICUpostoperatively, had
a significantly shorter LOS, and were more likely to be
discharged home than patients undergoing CEA. These
savings in hospital utilization are an interesting finding to
Table III. Patient characteristics
Variablea
CEA
(n  226)
CAS  EPD
(n  216)
Female sex 41 38
Age
Median, years 70 70
Average age  SD 70  9 70  10
80 years 14 21
Symptomatic 41 45
Prior CEA 12 29
Contralateral
Stenosis 31.3 24.5
Occlusion 6.6 11.1
Hypertension 94 92
Hyperlipidemia 82 87
Renal disease 9 11
Prior cerebrovascular accident 29 22
Prior transient ischemic attack 31 40
Diabetes 35 41
Prior myocardial infarction 15 13
Drug therapy
Clopidogrel 35 96
Acetylsalicylic acid 91 91
Warfarin 8 8
CAS, Carotid artery stenting; CEA, carotid endarterectomy; EPD, embolic
aData are presented as a percentage, unless otherwise indicated.
bCEA/EPD: comparison of CEA vs CAS  EPD; CEA/FRS: comparison
Table IV. Postoperative hospitalization course and
disposition at discharge
Outcome CEA CAS P
ICU stay (% in ICU) 41.6 27.7 .006
LOS, mean  SD days 2.9  3.4 1.6  1.9 .0001
Discharge to rehab 12/223 5/266 0.05
CVA or MI in those
discharged to rehab 4/11 4/5 .128
CAS, Carotid artery stenting; CEA, carotid endarterectomy; ICU, intensive
care unit; LOS, length of stay; NS, not significant.be considered when deciding on a therapy for patients. lThe limitations of this study include (1) the absence of
focused preoperative and postoperative neurologic exam-
nation by a neurologist, resulting in possible under repre-
entation of neurologic events, (2) lack of standardized
roponin levels and electrocardiogram tests in all patients,
ith the potential for missing silentMIs, (3) the differences
n postoperative admission to the ICU after CEA between
ractitioners at the two hospitals, and (4) that all FRS were
sed at one hospital with one surgeon performing all but
hree of these cases. This surgeon had outcomes with CEA
nd CAS  EPD that were consistent with the cumulative
esults.
However, these data are generated from a high-volume
enter with a number of practitioners directing carotid
herapy according to their treatment plan, with accurate
ccounting for the complications that affected their pa-
ients’ hospitalization, which lends credibility of these data
o patient care decisions in a manner that randomized
ontrolled trials cannot. An interesting finding is that these
esults are similar to those of the CREST trial, which has
een criticized for the expectation that such low complica-
ion rates will occur in all practices.
CVA morbidity continues to plague our population.10
rimary CVA prevention requires appropriate screening,
edical therapy, and use of surgical therapies.11 The clini-
al quagmire—most patients with asymptomatic carotid
rtery stenosis do not have CVAs, yet most CVAs occur in
atients with asymptomatic disease—speaks to the preva-
ence of carotid disease in our population. Initiatives to
tratify asymptomatic patients into groups more12 or less13
CAS  FRS
(n  53)
P b
Overall CEA/EPD CEA/FRS
42 .80 .55 .91
.62 .65 .49
69
69  11
19
32.7 .27 .43 .26
27 .001 .001 .017
42.6 .45 .09 .13
11.3 .042 .068 .17
86 .13 .50 .062
69 .014 .15 .046
2 .084 .46 .067
17 .087 .090 .065
46 .067 .058 .062
36 .44 .21 .85
21 .42 .63 .31
96 .001 .001 .001
81 .104 .81 .038
0 .019 .97 .006
tion device; FRS, flow reversal system; MI, myocardial infarction.
A vs CAS  FRS.protecikely to benefit from surgical therapy, as well as determin-
11
1
1
JOURNAL OF VASCULAR SURGERY
October 20111004 Brewster et aling which surgical therapy has better outcomes for which
asymptomatic patients, is critical as we enter the “century of
the brain.”
To best stratify the expected risks and benefits of avail-
able therapies for carotid artery stenosis in contemporary
times, patients would need to be prospectively randomized
to CEA, CASEPD, or CAS FRS for both symptomatic
and asymptomatic disease. The latter would have to meet
criteria for access vessels that the former choices would not.
Further, asymptomatic patients should include a medical
management arm. Finally, the trial would have to be com-
pleted in an expedited fashion with a shortened timeframe
(maybe 30-day follow-up) among practitioners who per-
form all of these procedures with excellent results so that
results could be compared while the technology is relatively
stagnant. Because this may not be realistic, practitioners
and referring physicians need tomake decisions and educate
their patients using randomized controlled trials, registry data,
and institutional results in the manner that best represents
what they can offer their patients. This study represents the
first comparative study between treatment options using the
FRS, and it certainly supports the hypothesis that proximal
flow reversal may limit stroke during CAS.
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Dr Carlos H. Timaran (Dallas, Tex). Dr Beaulieu & col-
leagues have presented a retrospective observational study about
their contemporary results of all carotid interventions performed at
their institution. As shown in this study, all carotid interventions
may offer excellent outcomes when these are applied to the appro-
priate patients. Because carotid artery stenting (CAS) is currently
reserved primarily for high-risk patients, the excellent outcomes
observed in this study clearly confirm its role in the treatment of
carotid stenosis. Moreover, the “zero” stroke and death rate with
CAS under flow reversal is indeed intriguing and probably the way
to improve neurologic outcomes with this intervention. Based on
the results of the current study, I have the following comments and
questions:
1. Although reporting overall results for carotid interventions is
important in terms of quality improvement, interpretation ofavoid comparing apples and oranges, reporting outcomes using
propensity scores and multivariate analyses for risk-adjustment
is advisable when treatment groups with different risk-profile
are assessed, as in the current study. In addition to the results
reported in the manuscript, did you analyze the data using any
type of risk-stratification? If so, what type of risk-adjustment did
you use and which were the results?
. We all are aware of your excellent outcomes with CEA under
local anesthesia, which could be used for high-risk patients. It
would be of particular interest to report the outcomes of carotid
endarterectomy (CEA) and CAS among patients at high-risk
because of comorbidities. Do you have these specific results? By
the way, I see that most of your endarterectomies are now
performed under general anesthesia? Why have you changed
the type of anesthesia used for CEA?. Another major problem with observational studies is the selec-
tion bias introduced to choose between therapies. It is remark-
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Volume 54, Number 4 Brewster et al 1005able that more than half the patients at your institution undergo
CAS, which in the U.S. is still reserved for high-risk patients.
Did you offer CAS to conventional-risk patients during the
study period? I understand that several of the patients under-
going CAS under flow reversal were enrolled in the EMPiRE
trial. Apart from this, how did you choose between therapies?
Were patients offered all treatments? Again, because CAS is
currently reserved for high-risk patients, this is probably un-
likely, unless you offered CAS to all comers or you enrolled
patients in trails that included conventional-risk patients. Did
you enroll patients in any of these trials?
4. Most octogenarians at your institution undergo CAS. The excel-
lent outcomes observed in those patients with CAS under flow
reversal clearly indicate that this is the method of choice for
embolic protection for the elderly. Do you use flow reversal in all
octogenarians undergoing CAS? How do you plan these proce-
dures?
5. Finally, and based on the results of your study and the current
regulatory restrictions, how do you choose between therapies
for carotid stenosis today?
I want to thank the authors for sending me their manuscript in
advance and the Association for the honor of discussing this
important study and the privilege of the floor.
Dr Robert Beaulieu. Thank you very much for your com-
ments, and thank you to the Southern Association Vascular Sur-
gery for allowing us to present this work. Both patients in the
carotid endarterectomy and carotid artery stenting cohort had
similar incidences of comorbidities and physiological risk factors.
The majority of patients undergoing carotid artery stenting did so
for anatomical risk factors. We did not subdivide stented patients
according to anatomic and physiologic risk, as our aim was to aresent results from physician-driven treatment decisions for pa-
ients with carotid artery stenosis.
Regarding the CEA under local anesthesia, the CEA was
erformed under local versus general anesthesia at the surgeon’s
reference. Several publications have had difficulty finding differ-
nces in outcomes between patients undergoing local or general
nesthesia. Also, Emory’s current outcomes are comparable to
hose under Dr Robert B. Smith II, who preferentially utilized
ocal anesthesia. Since there was no difference between the number
f medical high risk patients in the carotid endarterectomy and the
arotid artery stenting groups, it is not suprising that their out-
omes were also similar.
Further, looking at who was offered carotid artery stenting,
nly high-risk patients were offered stenting, with the exception of
small number of patients who participated in the CREST trial.
any patients are referred to us for stenting, and this may explain
he percentage of carotid artery stents performed.
Regarding octogenarians and flow reversal, currently our flow
eversal is used only for high risk symptomatic patients, due to the
ack of reimbursement and the lack of post-market study. Good
esults in octogenarians may be due to correct patient selection,
amely identifying hostile aortic arches or highly calcified or
hrombus-laden vessels that would probably benefit from CEA
ore so than flow reversal.
Finally, looking at our algorithm for treating patients with
ither carotid endarterectomy or carotid artery stenting, standard
isk patients are all offered CEA. Anatomically high-risk patients,
hether they are symptomatic or asymptomatic, are offered carotid
rtery stenting. And, physiologically high-risk patients that are
ymptomatic are offered carotid artery stenting, and those that are
symptomatic are given medical management.
